The future of cancer immunotherapy: microenvironment-targeting combinations

Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies of primary and secondary resistance to immunotherapy are multifaceted, deriving not only from tumor intrinsic factors, but also from the complex interplay between cancer a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell research Ročník 30; číslo 6; s. 507 - 519
Hlavní autoři: Murciano-Goroff, Yonina R., Warner, Allison Betof, Wolchok, Jedd D.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Singapore Springer Singapore 01.06.2020
Nature Publishing Group
Témata:
631/67/1059/2325
631/67/327
Animals
Antineoplastic Agents - therapeutic use
Biomedical and Life Sciences
Cancer
Cancer immunotherapy
Cell Biology
Design modifications
Drug development
Drug Resistance, Neoplasm
Etiology
Humans
Immunogenicity
Immunologic Factors - therapeutic use
Immunotherapy
Life Sciences
Molecular Targeted Therapy
Neoplasms - therapy
Resistance factors
Review
Review Article
Tumor Microenvironment - drug effects
Tumors
ISSN:1001-0602, 1748-7838, 1748-7838
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies of primary and secondary resistance to immunotherapy are multifaceted, deriving not only from tumor intrinsic factors, but also from the complex interplay between cancer and its microenvironment. In addressing frontiers in clinical immunotherapy, we describe two categories of approaches to the design of novel drugs and combination therapies: the first involves direct modification of the tumor, while the second indirectly enhances immunogenicity through alteration of the microenvironment. By systematically addressing the factors that mediate resistance, we are able to identify mechanistically-driven novel approaches to improve immunotherapy outcomes.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1001-0602
1748-7838
1748-7838
DOI:10.1038/s41422-020-0337-2